{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:54:23Z","timestamp":1791726863588,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06109-w","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T18:05:25Z","timestamp":1737741925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CDCA4 promotes bladder cancer progression by JAK\/STAT signaling pathway"],"prefix":"10.1007","volume":"151","author":[{"given":"Peng","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"3","key":"6109_CR13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1006\/bcmd.2001.0434","volume":"27","author":"JM Abdullah","year":"2001","unstructured":"Abdullah JM, Jing X, Spassov DS, Nachtman RG, Jurecic R (2001) Cloning and characterization of Hepp, a novel gene expressed preferentially in hematopoietic progenitors and mature blood cells. Blood Cells Mol Dis 27(3):667\u2013676","journal-title":"Blood Cells Mol Dis"},{"issue":"10","key":"6109_CR29","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/apm.12889","volume":"126","author":"B Ahn","year":"2018","unstructured":"Ahn B, Chae YS, Kim CH, Lee Y, Lee JH, Kim JY (2018) Tumor microenvironmental factors have prognostic significances in advanced gastric cancer. APMIS 126(10):814\u2013821","journal-title":"APMIS"},{"issue":"7","key":"6109_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.molmed.2024.04.004","volume":"30","author":"R Ben-David","year":"2024","unstructured":"Ben-David R, Galsky MD, Sfakianos JP (2024) Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer. Trends Mol Med 30(7):686\u2013697","journal-title":"Trends Mol Med"},{"key":"6109_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bbrc.2021.02.072","volume":"548","author":"X Bian","year":"2021","unstructured":"Bian X, Sun YM, Wang LM, Shang YL (2021) ELK1-induced upregulation lncRNA LINC02381 accelerates the osteosarcoma tumorigenesis through targeting CDCA4 via sponging miR-503-5p. Biochem Biophys Res Commun 548:112\u2013119","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"6109_CR31","doi-asserted-by":"publisher","first-page":"152872","DOI":"10.1016\/j.prp.2020.152872","volume":"216","author":"Q Chen","year":"2020","unstructured":"Chen Q, Zhou L, Ye X, Tao M, Wu J (2020) Mir-145-5p suppresses proliferation, metastasis and EMT of colorectal cancer by targeting CDCA3. Pathol Res Pract 216(4):152872","journal-title":"Pathol Res Pract"},{"key":"6109_CR23","doi-asserted-by":"publisher","first-page":"650250","DOI":"10.3389\/fcell.2021.650250","volume":"9","author":"M Chen","year":"2021","unstructured":"Chen M, Xiao L, Dai G, Lu P, Zhang Y, Li Y, Ni M, Rui Y (2021) Inhibition of JAK-STAT signaling pathway alleviates Age-related phenotypes in Tendon Stem\/Progenitor cells. Front Cell Dev Biol 9:650250","journal-title":"Front Cell Dev Biol"},{"issue":"10364","key":"6109_CR6","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","volume":"400","author":"E Comperat","year":"2022","unstructured":"Comperat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, Stenzl A, Thoeny HC, Witjes JA (2022) Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet 400(10364):1712\u20131721","journal-title":"Lancet"},{"issue":"4","key":"6109_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/MOU.0000000000001182","volume":"34","author":"I Ertl","year":"2024","unstructured":"Ertl I, Shariat SF, Berger W, Englinger B (2024) Preclinical models for bladder cancer therapy research. Curr Opin Urol 34(4):244\u2013250","journal-title":"Curr Opin Urol"},{"issue":"1","key":"6109_CR32","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1186\/s12885-019-5793-z","volume":"19","author":"Y Feng","year":"2019","unstructured":"Feng Y, Qian W, Zhang Y, Peng W, Li J, Gu Q, Ji D, Zhang Z, Wang Q, Zhang D et al (2019) CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT\/CCND1 pathway in vitro and in vivo. BMC Cancer 19(1):576","journal-title":"BMC Cancer"},{"issue":"8","key":"6109_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/1759-7714.14800","volume":"14","author":"S Feng","year":"2023","unstructured":"Feng S, Cao H, Sui Y, Shen Z, Wu J, Ma R, Feng J (2023) CDCA4 interacts with IGF2BP1 to regulate lung adenocarcinoma proliferation via the PI3K\/AKT pathway. Thorac Cancer 14(8):724\u2013735","journal-title":"Thorac Cancer"},{"issue":"9","key":"6109_CR33","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.7150\/jca.35372","volume":"11","author":"G Fu","year":"2020","unstructured":"Fu G, Xu Z, Chen X, Pan H, Wang Y, Jin B (2020) CDCA5 functions as a tumor promoter in bladder cancer by dysregulating mitochondria-mediated apoptosis, cell cycle regulation and PI3k\/AKT\/mTOR pathway activation. J Cancer 11(9):2408\u20132420","journal-title":"J Cancer"},{"key":"6109_CR24","doi-asserted-by":"crossref","unstructured":"Gilyazova I, Enikeeva K, Rafikova G, Kagirova E, Sharifyanova Y, Asadullina D, Pavlov V (2023) Epigenetic and immunological features of bladder Cancer. Int J Mol Sci 24(12)","DOI":"10.3390\/ijms24129854"},{"issue":"47","key":"6109_CR8","doi-asserted-by":"publisher","first-page":"35633","DOI":"10.1074\/jbc.M603800200","volume":"281","author":"R Hayashi","year":"2006","unstructured":"Hayashi R, Goto Y, Ikeda R, Yokoyama KK, Yoshida K (2006) CDCA4 is an E2F transcription factor family-induced nuclear factor that regulates E2F-dependent transcriptional activation and cell proliferation. J Biol Chem 281(47):35633\u201335648","journal-title":"J Biol Chem"},{"key":"6109_CR37","doi-asserted-by":"publisher","first-page":"110505","DOI":"10.1016\/j.intimp.2023.110505","volume":"121","author":"WM Hu","year":"2023","unstructured":"Hu WM, Liu SQ, Zhu KF, Li W, Yang ZJ, Yang Q, Zhu ZC, Chang J (2023) The ALOX5 inhibitor Zileuton regulates tumor-associated macrophage M2 polarization by JAK\/STAT and inhibits pancreatic cancer invasion and metastasis. Int Immunopharmacol 121:110505","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"6109_CR38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s10120-024-01480-y","volume":"27","author":"Y Ito","year":"2024","unstructured":"Ito Y, Kanda M, Sasahara M, Tanaka C, Shimizu D, Umeda S, Inokawa Y, Hattori N, Hayashi M, Nakayama G et al (2024) Killer cell lectin-like receptor G2 facilitates aggressive phenotypes of gastric cancer cells via dual activation of the ERK1\/2 and JAK\/STAT pathways. Gastric Cancer 27(3):506\u2013518","journal-title":"Gastric Cancer"},{"issue":"11","key":"6109_CR30","doi-asserted-by":"publisher","first-page":"10875","DOI":"10.1007\/s11033-022-07788-1","volume":"49","author":"E Jamasbi","year":"2022","unstructured":"Jamasbi E, Hamelian M, Hossain MA, Varmira K (2022) The cell cycle, cancer development and therapy. Mol Biol Rep 49(11):10875\u201310883","journal-title":"Mol Biol Rep"},{"issue":"1","key":"6109_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s13046-019-1428-0","volume":"38","author":"L Jiang","year":"2019","unstructured":"Jiang L, Zhao XH, Mao YL, Wang JF, Zheng HJ, You QS (2019) Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK\/STAT signaling pathway by targeting STAT5 and STAT6. J Exp Clin Cancer Res 38(1):465","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"6109_CR15","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1080\/0886022X.2021.1994994","volume":"43","author":"S Li","year":"2021","unstructured":"Li S, Qin C, Chen Y, Wei D, Tan Z, Meng J (2021) Implications of cell division cycle associated 4 on the Wilm\u2019s tumor cells viability via AKT\/mTOR signaling pathway. Ren Fail 43(1):1470\u20131478","journal-title":"Ren Fail"},{"issue":"19","key":"6109_CR21","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1111\/jcmm.17863","volume":"27","author":"L Li","year":"2023","unstructured":"Li L, Zhang Y, Hu W, Zou F, Ning J, Rao T, Ruan Y, Yu W, Cheng F (2023) MTHFD2 promotes PD-L1 expression via activation of the JAK\/STAT signalling pathway in bladder cancer. J Cell Mol Med 27(19):2922\u20132936","journal-title":"J Cell Mol Med"},{"issue":"1","key":"6109_CR9","doi-asserted-by":"publisher","first-page":"e0295346","DOI":"10.1371\/journal.pone.0295346","volume":"19","author":"R Li","year":"2024","unstructured":"Li R, Chen Y, Yang B, Li Z, Wang S, He J, Zhou Z, Li X, Li J, Sun Y et al (2024) Integrated bioinformatics analysis and experimental validation identified CDCA families as prognostic biomarkers and sensitive indicators for rapamycin treatment of glioma. PLoS ONE 19(1):e0295346","journal-title":"PLoS ONE"},{"issue":"1","key":"6109_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-021-01377-9","volume":"20","author":"ZK Liu","year":"2021","unstructured":"Liu ZK, Li C, Zhang RY, Wei D, Shang YK, Yong YL, Kong LM, Zheng NS, Liu K, Lu M et al (2021) EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK\/STAT signaling. Mol Cancer 20(1):79","journal-title":"Mol Cancer"},{"issue":"5","key":"6109_CR7","doi-asserted-by":"publisher","first-page":"e18101","DOI":"10.1111\/jcmm.18101","volume":"28","author":"J Liu","year":"2024","unstructured":"Liu J, Gao Y, Song C, Liao W, Meng L, Yang S, Xiong Y (2024) Immunotherapeutic prospects and progress in bladder cancer. J Cell Mol Med 28(5):e18101","journal-title":"J Cell Mol Med"},{"issue":"6","key":"6109_CR1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y (2022) Epidemiology, screening, and Prevention of bladder Cancer. Eur Urol Oncol 5(6):628\u2013639","journal-title":"Eur Urol Oncol"},{"key":"6109_CR26","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L (2024) Advances in diagnosis and treatment of bladder cancer. BMJ 384:e076743","journal-title":"BMJ"},{"key":"6109_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.critrevonc.2018.01.010","volume":"123","author":"M Lopez-Lazaro","year":"2018","unstructured":"Lopez-Lazaro M (2018) The stem cell division theory of cancer. Crit Rev Oncol Hematol 123:95\u2013113","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"6109_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2022.01.075","volume":"33","author":"M Moschini","year":"2022","unstructured":"Moschini M, Gandaglia G, Deho F, Salonia A, Briganti A, Montorsi F (2022) Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(5):561","journal-title":"Ann Oncol"},{"issue":"5","key":"6109_CR5","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00345-020-03474-8","volume":"39","author":"JL Pfail","year":"2021","unstructured":"Pfail JL, Katims AB, Alerasool P, Sfakianos JP (2021) Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions. World J Urol 39(5):1319\u20131329","journal-title":"World J Urol"},{"issue":"7","key":"6109_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41585-022-00620-2","volume":"19","author":"L Stone","year":"2022","unstructured":"Stone L (2022) Biomarkers for bladder cancer diagnosis, prognosis, monitoring and treatment. Nat Rev Urol 19(7):383","journal-title":"Nat Rev Urol"},{"key":"6109_CR35","doi-asserted-by":"publisher","first-page":"147975","DOI":"10.1016\/j.gene.2023.147975","volume":"895","author":"J Tan","year":"2024","unstructured":"Tan J, Chen F, Wang J, Li J, Ouyang B, Li X, Li Y, Zhang W, Jiang Y (2024) ALKBH5 promotes the development of lung adenocarcinoma by regulating the polarization of M2 macrophages through CDCA4. Gene 895:147975","journal-title":"Gene"},{"issue":"15","key":"6109_CR10","doi-asserted-by":"publisher","first-page":"6504","DOI":"10.1158\/0008-5472.CAN-05-0351","volume":"65","author":"DJ Tang","year":"2005","unstructured":"Tang DJ, Hu L, Xie D, Wu QL, Fang Y, Zeng Y, Sham JS, Guan XY (2005) Oncogenic transformation by SEI-1 is associated with chromosomal instability. Cancer Res 65(15):6504\u20136508","journal-title":"Cancer Res"},{"issue":"3","key":"6109_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41419-018-0362-y","volume":"9","author":"X Tian","year":"2018","unstructured":"Tian X, Liu C, Wang X, Wang F, Wang L, Xu L, Ma J, Gao Y, Bao Y, Wang F et al (2018) Sei-1 promotes double minute chromosomes formation through activation of the PI3K\/Akt\/BRCA1-Abraxas pathway and induces double-strand breaks in NIH-3T3 fibroblasts. Cell Death Dis 9(3):341","journal-title":"Cell Death Dis"},{"issue":"4","key":"6109_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino AV, Kanno Y, O\u2019Shea JJ (2017) Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol 18(4):374\u2013384","journal-title":"Nat Immunol"},{"issue":"5","key":"6109_CR36","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.21037\/tcr-23-569","volume":"12","author":"B Wang","year":"2023","unstructured":"Wang B, Chen L, Li Q, Zhou J, Jin W (2023) LINC00638\/hsa-miR-29b-3p axis-mediated high expression of CDCA4 correlates with tumor immune infiltration and hepatocellular carcinoma progression. Transl Cancer Res 12(5):1290\u20131306","journal-title":"Transl Cancer Res"},{"issue":"8","key":"6109_CR12","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/j.1365-2443.2005.00881.x","volume":"10","author":"R Watanabe-Fukunaga","year":"2005","unstructured":"Watanabe-Fukunaga R, Iida S, Shimizu Y, Nagata S, Fukunaga R (2005) SEI family of nuclear factors regulates p53-dependent transcriptional activation. Genes Cells 10(8):851\u2013860","journal-title":"Genes Cells"},{"key":"6109_CR22","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","volume":"80","author":"P Xin","year":"2020","unstructured":"Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Ma H, Wei D, Sun S (2020) The role of JAK\/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol 80:106210","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"6109_CR14","first-page":"1507","volume":"17","author":"Y Xu","year":"2018","unstructured":"Xu Y, Wu X, Li F, Huang D, Zhu W (2018) CDCA4, a downstream gene of the Nrf2 signaling pathway, regulates cell proliferation and apoptosis in the MCF\u20137\/ADM human breast cancer cell line. Mol Med Rep 17(1):1507\u20131512","journal-title":"Mol Med Rep"},{"issue":"1","key":"6109_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, Bao Z, Lu J, Li L (2023) Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther 8(1):204","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"6109_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, van de Fransen EE, Horenblas S, Drabick JJ (2016) Neoadjuvant chemotherapy for muscle-invasive bladder Cancer: a systematic review and two-step Meta-analysis. Oncologist 21(6):708\u2013715","journal-title":"Oncologist"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06109-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06109-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06109-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T21:22:06Z","timestamp":1741814526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06109-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["6109"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06109-w","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors of this study agreed with the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}